The decision to discontinue SerpinPC follows the approval of Hympavzi, an antibody-based treatment designed to increase ...

The CDC estimates about 10 in 100,000 people have hemophilia A. • Hemophilia B: Hemophilia B happens when you don’t have enough clotting factor 9 (factor IX.) The CDC estimates about 3 in ...

There’s a new hope for people living with the rare blood disorder hemophilia B. The FDA recently approved a new gene therapy treatment for those who suffer from the debilitating condition.

Oct. 14, 2024 – The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

Clotting proteins missing or are defective in hemophilia can directly affect the activity of cells responsible for bone ...

A Summerville man became the first person in South Carolina to undergo potentially life-changing gene therapy. The treatment took place Thursday morning at Prisma Health's Hemophilia Treatment Center ...

Friday Headlines: 38 y/o Brent Maloy is the first person in SC to undergo gene therapy treatment after living with Hemophilia ...

As many as 30% of people living with severe hemophilia A develop inhibitors such as TFPI, which can be produced by the body’s immune response to clotting factors in replacement therapy, often limiting ...

FIX in hemophilia B), impacting more than 800,000 people globally. Results from the Phase 3 BASIS trial (NCT03938792) supported the FDA approval of Hympavzi. In the study, Hympavzi reduced the ...

The approval is based on an open-label, multicenter study of 116 adult and pediatric male patients with either severe hemophilia A or severe hemophilia B, both without inhibitors. For the first ...